Literature DB >> 32799714

Vitamin D status in patients with autoimmune bullous dermatoses: a meta-analysis.

Miao Yang1,2, Haijing Wu1,2, Ming Zhao1,2, Hai Long1,2, Qianjin Lu1,2.   

Abstract

BACKGROUND: The association between autoimmune bullous dermatoses (AIBD) and serum vitamin D levels has been revealed by some studies, however, inconsistent.
OBJECTIVES: We aimed to evaluate the difference in vitamin D status between AIBD patients and controls.
METHODS: We searched the studies about the vitamin D status of AIBD patients in electronic databases published before January 2020. Mean difference (MD) and 95% confidence intervals (CI) of eligible studies were calculated in meta-analyses of 25(OH)D levels. Pooled odds ratio (OR) and 95%CI were used in analyses of the prevalence of hypovitaminosis D. Different subgroup analyses, sensitivity analyses and publication bias assessment were conducted.
RESULTS: We included nine case-control studies in the meta-analysis. Vitamin D level was significantly lower in both pemphigus (MD: -7.02, 95%CI: -10.30 to -3.74) and bullous pemphigoid (BP) (MD: -6.37, 95%CI: -12.15 to -0.58) patients than that in controls. Active pemphigus patients were at higher risk of presenting hypovitaminosis D (OR: 6.95, 95%CI: 1.37-35.25).
CONCLUSIONS: Abnormal vitamin D status are more common in AIBD patients than that in general population. Therefore, regular monitoring of vitamin D levels and vitamin D supplementation should be considered as part of the management strategy for AIBD.

Entities:  

Keywords:  Autoimmune bullous dermatoses; meta-analysis; vitamin D

Year:  2020        PMID: 32799714     DOI: 10.1080/09546634.2020.1810606

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  1 in total

1.  Bullous pemphigoid anti-BP180-NC16A autoantibody reactivity in healthy individuals is associated with marked hypovitaminosis D and Th2-like cytokine predominance.

Authors:  Stefan Tukaj; Katja Bieber; Wiebke Prüßmann; Jasper N Prüßmann; Enno Schmidt; Detlef Zillikens; Ralf J Ludwig; Michael Kasperkiewicz
Journal:  Arch Dermatol Res       Date:  2022-08-12       Impact factor: 3.033

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.